Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 2067727
PUBLISHER: Grand View Research | PRODUCT CODE: 2067727
U.S. Non-Invasive Cancer Diagnostics Market Size, Share, & Trends Analysis Report By Product (Pathology-based Instruments, Imaging Instruments), By Technology, By Indication, By End User, And Segment Forecasts, 2026 - 2033
PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
U.S. Non-Invasive Cancer Diagnostics Market Summary
The U.S. non-invasive cancer diagnostics market size was estimated at USD 27.08 billion in 2025 and is projected to reach USD 47.52 billion in 2033, growing at a CAGR of 7.4% from 2026 to 2033. The growth is driven by the continuous advancements in diagnostic technologies, the rising prevalence of cancer, and increasing initiatives by both private and public organizations aimed at enhancing early detection and treatment.
The U.S. non-invasive cancer diagnostics industry's growth is further driven by strategic expansion initiatives by companies to strengthen commercialization and innovation capabilities. For instance, in June 2025, Dxcover launched its U.S. headquarters in Nashville to accelerate the commercialization of its AI-powered PANAROMIC cancer test in the world's largest life sciences market. The new facility will support partnerships, local manufacturing, and R&D, strengthening its non-invasive, cost-effective cancer screening platform and expanding early detection capabilities.
In addition, increasing demand for early, accurate, and minimally invasive detection methods that improve patient outcomes. Advancements in blood-based and multi-cancer screening technologies are further supporting timely diagnosis and wider clinical adoption. For instance, in September 2025, Exact Sciences launched Cancerguard, a first-of-its-kind multi-cancer early detection blood test in the U.S., capable of identifying over 50 cancer types through multiple biomarkers. The test aims to address gaps in early diagnosis, demonstrating strong sensitivity and high specificity, and is expected to improve outcomes by enabling earlier detection alongside existing screening methods.
U.S. Non-invasive Cancer Diagnostics Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. non-invasive cancer diagnostics market report based on product, technology, indication, and end user:
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Instruments
- Pathology-based Instruments
- Polymerase Chain Reaction (PCR) Instruments
- Next-generation Sequencing (NGS) Instruments
- Microarrays
- Imaging Instruments
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT)
- Positron Emission Tomography (PET)
- Mammography
- Others (Ultrasound, etc.)
- Consumables
- Kits & Reagents
- Technology Outlook (Revenue, USD Million, 2021 - 2033)
- Imaging
- Liquid Biopsy
- Immunoassay
- Indication Outlook (Revenue, USD Million, 2021 - 2033)
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Blood Cancer
- Liver Cancer
- Cervical Cancer
- Skin Cancer
- Others (Thyroid Cancer, etc.)
- End User Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Diagnostic Laboratories
- Others (Academic & Research Institutes, etc.)
Product Code: GVR-4-68040-911-6
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Technology
- 1.2.3. Indication
- 1.2.4. End User
- 1.2.5. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. U.S. Non-Invasive Cancer Diagnostic Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
- 3.3. U.S. Non-Invasive Cancer Diagnostic Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.3.1. Industry Analysis - Porter's
- 3.4. U.S. Non-Invasive Cancer Diagnostic Market: Pipeline Analysis
Chapter 4. U.S. Non-Invasive Cancer Diagnostic Market: Product Estimates & Trend Analysis
- 4.1. Product Segment Dashboard
- 4.2. U.S. Non-Invasive Cancer Diagnostic Market: Product Movement Analysis
- 4.3. U.S. Non-Invasive Cancer Diagnostic Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
- 4.4. Instruments
- 4.4.1. Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.2. Pathology-based Instruments
- 4.4.2.1. Pathology-based Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.2.2. Polymerase Chain Reaction (PCR) Instruments
- 4.4.2.2.1. Polymerase Chain Reaction (PCR) Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.2.3. Next-generation Sequencing (NGS) Instruments
- 4.4.2.3.1. Next-generation Sequencing (NGS) Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.2.4. Microarrays
- 4.4.2.4.1. Microarrays Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.3. Imaging Instruments
- 4.4.3.1. Imaging Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.3.2. Magnetic Resonance Imaging (MRI)
- 4.4.3.2.1. Magnetic Resonance Imaging (MRI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.3.3. Computed Tomography (CT)
- 4.4.3.3.1. Computed Tomography (CT) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.3.4. Positron Emission Tomography (PET)
- 4.4.3.4.1. Positron Emission Tomography (PET) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.3.5. Mammography
- 4.4.3.5.1. Mammography Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.3.6. Others (Ultrasound, etc.)
- 4.4.3.6.1. Others (Ultrasound, etc.) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5. Consumables
- 4.5.1. Consumables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6. Kits & Reagents
- 4.6.1. Kits & Reagents Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. U.S. Non-Invasive Cancer Diagnostic Market: Technology Estimates & Trend Analysis
- 5.1. Technology Segment Dashboard
- 5.2. U.S. Non-Invasive Cancer Diagnostic Market: Technology Movement Analysis
- 5.3. U.S. Non-Invasive Cancer Diagnostic Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
- 5.4. Imaging
- 5.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 5.5. Liquid Biopsy
- 5.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 5.6. Immunoassay
- 5.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
Chapter 6. Non-Invasive Cancer Diagnostic Market: Indication Business Analysis
- 6.1. Indication Segment Dashboard
- 6.2. U.S. Non-Invasive Cancer Diagnostic Market: Indication Movement Analysis
- 6.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
- 6.4. Lung Cancer
- 6.4.1. Lung Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Breast Cancer
- 6.5.1. Breast Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. Colorectal Cancer
- 6.6.1. Colorectal Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.7. Prostate Cancer
- 6.7.1. Prostate Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.8. Blood Cancer
- 6.8.1. Blood Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.9. Liver Cancer
- 6.9.1. Liver Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.10. Cervical Cancer
- 6.10.1. Cervical Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.11. Skin Cancer
- 6.11.1. Skin Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.12. Others (Thyroid Cancer, etc.)
- 6.12.1. Others (Thyroid Cancer, etc.) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Non-Invasive Cancer Diagnostic Market: End User Business Analysis
- 7.1. End User Segment Dashboard
- 7.2. U.S. Non-Invasive Cancer Diagnostic Market: End User Movement Analysis
- 7.3. Market Size & Forecasts and Trend Analysis, by End User, 2021 to 2033 (USD Million)
- 7.4. Hospitals
- 7.4.1. Hospitals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Diagnostic Laboratories
- 7.5.1. Diagnostic Laboratories Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Others (Academic & Research Institutes, etc.)
- 7.6.1. Others (Academic & Research Institutes, etc.) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.3. Vendor Landscape
- 8.3.1. Key company heat map analysis, 2025
- 8.4. Company Profiles
- 8.4.1. Abbott Laboratories
- 8.4.1.1. Company overview
- 8.4.1.2. Financial performance
- 8.4.1.3. Product benchmarking
- 8.4.1.4. Strategic initiatives
- 8.4.2. GE Healthcare
- 8.4.2.1. Company overview
- 8.4.2.2. Financial performance
- 8.4.2.3. Service benchmarking
- 8.4.2.4. Strategic initiatives
- 8.4.3. Siemens Healthineers AG
- 8.4.3.1. Company overview
- 8.4.3.2. Financial performance
- 8.4.3.3. Service benchmarking
- 8.4.3.4. Strategic initiatives
- 8.4.4. Koninklijke Philips N.V.
- 8.4.4.1. Company overview
- 8.4.4.2. Financial performance
- 8.4.4.3. Service benchmarking
- 8.4.4.4. Strategic initiatives
- 8.4.5. Canon Medical Systems
- 8.4.5.1. Company overview
- 8.4.5.2. Financial performance
- 8.4.5.3. Service benchmarking
- 8.4.5.4. Strategic initiatives
- 8.4.6. F. Hoffmann-La Roche Ltd
- 8.4.6.1. Company overview
- 8.4.6.2. Financial performance
- 8.4.6.3. Service benchmarking
- 8.4.6.4. Strategic initiatives
- 8.4.7. Illumina, Inc.
- 8.4.7.1. Company overview
- 8.4.7.2. Financial performance
- 8.4.7.3. Service benchmarking
- 8.4.7.4. Strategic initiatives
- 8.4.8. Guardant Health, Inc.
- 8.4.8.1. Company overview
- 8.4.8.2. Financial performance
- 8.4.8.3. Service benchmarking
- 8.4.8.4. Strategic initiatives
- 8.4.9. Thermo Fisher Scientific Inc.
- 8.4.9.1. Company overview
- 8.4.9.2. Financial performance
- 8.4.9.3. Service benchmarking
- 8.4.9.4. Strategic initiatives
- 8.4.10. FONAR Corporation
- 8.4.10.1. Financial performance
- 8.4.10.2. Service benchmarking
- 8.4.10.3. Strategic initiatives
- 8.4.1. Abbott Laboratories
Product Code: GVR-4-68040-911-6
List of Tables
- Table 1 List of abbreviations
- Table 2 U.S. non-invasive cancer diagnostic market, by product, 2021 - 2033 (USD Million)
- Table 3 U.S. non-invasive cancer diagnostic market, by technology, 2021 - 2033 (USD Million)
- Table 4 U.S. non-invasive cancer diagnostic market, by indication, 2021 - 2033 (USD Million)
- Table 5 U.S. non-invasive cancer diagnostic market, by end user, 2021 - 2033 (USD Million)
- Table 6 Financial performance
- Table 7 Key companies undergoing expansions
- Table 8 Key companies undergoing acquisitions
- Table 9 Key companies undergoing collaborations
- Table 10 Key companies launching new products/services
- Table 11 Key companies undergoing partnerships
- Table 12 Key companies undertaking other strategies
List of Figures
- Fig. 1 Market research process
- Fig. 2 Data triangulation techniques
- Fig. 3 Primary research pattern
- Fig. 4 Primary interviews
- Fig. 5 Market research approaches
- Fig. 6 Value-chain-based sizing & forecasting
- Fig. 7 QFD modeling for market share assessment
- Fig. 8 Market formulation & validation
- Fig. 9 U.S. non-invasive cancer diagnostic market: market outlook
- Fig. 10 U.S. non-invasive cancer diagnostic market competitive insights
- Fig. 11 Parent market outlook
- Fig. 12 Related/ancillary market outlook
- Fig. 13 Penetration and growth prospect mapping
- Fig. 14 Industry value chain analysis
- Fig. 15 U.S. non-invasive cancer diagnostic market driver impact
- Fig. 16 U.S. non-invasive cancer diagnostic market restraint impact
- Fig. 17 U.S. non-invasive cancer diagnostic market strategic initiatives analysis
- Fig. 18 U.S. non-invasive cancer diagnostic market: product movement analysis
- Fig. 19 U.S. non-invasive cancer diagnostic market: product outlook and key takeaways
- Fig. 20 Instruments market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 21 Pathology-based instruments market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 22 Polymerase Chain Reaction (PCR) Instruments market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 23 Next-generation Sequencing (NGS) Instruments market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 24 Microarrays market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 25 Imaging instruments market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 26 Magnetic Resonance Imaging (MRI) market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 27 Computed Tomography (CT) market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 28 Positron Emission Tomography (PET) market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 29 Mammography market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 30 Others (Ultrasound, etc.) market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 31 Consumables market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 32 Kits & reagents market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 33 U.S. non-invasive cancer diagnostic market: by technology, movement analysis
- Fig. 34 U.S. non-invasive cancer diagnostic market: technology outlook and key takeaways
- Fig. 35 Imaging market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 36 Liquid biopsy market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 37 Immunoassay market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 38 U.S. non-invasive cancer diagnostic market: by indication, movement analysis
- Fig. 39 U.S. non-invasive cancer diagnostic market: indication outlook and key takeaways
- Fig. 40 Lung cancer market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 41 Breast cancer market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 42 Colorectal cancer market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 43 Prostate market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 44 Blood market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 45 Liver market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 46 Cervical market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 47 Skin market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 48 Others (Thyroid Cancer, etc.) market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 49 U.S. non-invasive cancer diagnostic market: by end user, movement analysis
- Fig. 50 U.S. non-invasive cancer diagnostic market: end user outlook and key takeaways
- Fig. 51 Hospitals market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 52 Diagnostic laboratories market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 53 Others (Academic & Research Institutes, etc.) market estimates and forecasts, 2021 - 2033 (USD Million)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.